Zamir Brelvi, MD
Gastroenterology · Newark, NJNPI 1740213297
Payments from drug & device makers
Across 1,183 payments — averaging $345.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$104K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100K
- Spectra Medical Devices, LLC$50K
- Madrigal Pharmaceuticals$35K
- AbbVie$31K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- plus $67K from 33 others
Across 3 payments — averaging $321.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$965
What the payments were for
- Royalty or licence$50,00013%
- Consulting fees$15,7684%
- Speaking & faculty fees$282,32272%
- Travel & lodging$14,5444%
- Food & beverage$28,7147%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$102,492
- XIFAXAN$64,760
- NumStat Antiseptic and Pain Relieving Prep Pad$50,000
- LINZESS$37,160
- REZDIFFRA$33,120
- Alinia$32,700
- TRULANCE$30,625
- Motegrity$20,229
- Talicia$6,997
- ZENPEP$5,475
- Reltone 200 Mg$3,760
- Reltone 400 Mg$3,760
- GLYCATE$3,603
- ZEPOSIA$1,331
- IQIRVO$550
- IBSRELA$380
- INTERSTIM$297
- Livdelzi$246
- Vemlidy$239
- Rinvoq$236
How this compares
$408,349 in reported general payments places this provider in the 95th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 53 | $173,616 |
| CreonLipase/Protease/Amylase | 63 | $158,844 |
| XifaxanRifaximin | 50 | $119,209 |
| LinzessLinaclotide | 82 | $55,580 |
| IbsrelaTenapanor Hcl | 19 | $32,829 |
| MotegrityPrucalopride Succinate | 16 | $11,035 |
| Famotidine | 727 | $10,284 |
| VascepaIcosapent Ethyl | 20 | $10,043 |
| TrulancePlecanatide | 19 | $10,019 |
| LivaloPitavastatin Calcium | 13 | $7,400 |
| Dexlansoprazole DrDexlansoprazole | 24 | $7,084 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 84 | $5,081 |
| Ursodiol | 28 | $3,892 |
| Mesalamine | 14 | $2,482 |
| Budesonide EcBudesonide | 21 | $2,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $31,280 | $214,424145 claims |
| Aimmune Therapeutics, Inc.Zenpep | $5,926 | $173,61653 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $99,624 | $129,22869 claims |
| Ardelyx, Inc.Ibsrela | $728 | $32,82919 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $21,385 | $11,03516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Newark
- Jamil ShahNewark$55K
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
- Neil NagariaToms River$442K
- Adam ElfantMount Laurel$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.